Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
IMO it'd be earlier (EPC Signing); first, "Q2" covers May too; secondly, one of the Broker Notes mentioned "end of May", maybe it was a slip of the tongue? thirdly, all these inside trades "rushing" to beat the RNS issue indicate sooner, rather than later; in any case, the SP didn't double in 4 days just like that; something's up.
FWIW, this is the growth plan to 2030; I assume APTA will be a partner in this journey (especially re Oncology);
"AstraZeneca set out its ambition to achieve USD80 billion in annual revenue by the end of the decade, as the pharmaceutical firm looks to bolster its oncology offering, its rare disease portfolio and launch 20 new treatments. The revenue target would represent a 75% jump from the USD45.81 billion it achieved in 2023. Chief Executive Officer Pascal Soriot said ahead of an investor day: "Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious USD45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for USD80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than USD5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade."
Seems everyone is waiting for the RNS; the insiders have taken their "positions" and holders are waiting for the next jump upwards; the SP is taking a breather from the quick rise to 1p, not many people sold into that rally, which is encouraging.
Complete silence by the Co might indicate - IMO- that we are very close to the EPC getting signed, so they couldn't just release an RNS to blame the rise on "rumours" etc.
Profit taking, some people are getting the jitters after last week's run.
Do we want the RNS next week?? Seems the insider buys are driving the SP up, even in the absence of the RNS; obviously the MMaker is aware of the coming re-rating news, hence their gradual increase of the SP on usual trade volumes (absence of sellers helps too); only question is, is the SP hitting 2p before, or at issue of, the RNS?
And if 2p is hit next week (mkt cap of 80mln), what will the SP be when the financing is announced?
GLA!
Over 1p now, to SELL and BUY
Believe it or not, all those trades at 0.966 are NOT Buys, they are SELLS; all sells currently being absorbed.
99, the Directors CANNOT (legally) trade on Inside Information; but, with Institutional investors/shareholders (Board participants) in 5 continents, it's very likely that some price-sensitive information may have leaked out!
In any case, these big 1mln+ trades are definitely Insiders buying (not speculators, who might be caught out); so, expect a good RNS soon. IMO
There is no RNS, that's the point; normally, when the SP doubles without news, the Co (any Co) should announce that the SP is moving (up or down) for XY reason (to prevent trading just on rumours); unless of course they issue the real thing ie an RNS justifying the mysterious rise (in KP's case, the EPC signing, for example).
IMO, they'd have already issued an RNS explaining why the SP has doubled ON NO NEWS! Clear indication of insider trading.
Might be that the RNS, still expected, would be about the signing having taken place already in China? And that financing news are close? they always say "up to 6 weeks from EPC signing" but, since they must already seen the final EPC (and had plenty of time to review etc), the financing could also be a done deal?
Seems that sellers are keeping low;
Mitch,
It's not just the SP then (March 2018,) when the Co was floated (SP was 10p) but # of shares (860mln appx) too; the Mkt Cap was 86 million and the EPC was supposedly 1 year away (or so). Today, 5 years later, with EPC almost done, + extra Optimisation Study done, +further engineering design works by POWERCHINA, the Mkt cap is just 30mln.
The EPC is imminent, would going back to 86mln be unreasonable to expect i.e. 3-4x rise i.e SP at 2-3p?
Apologies, BID at 0.76!!
Glad we got rid of a few more short-term speculators, selling this morning at 0.60 - now BID at 0.68.
Let's hope this continues, small steps up until the RNS is released.
Postponed by a further 2 years, announced today; FWIW...less supply in global markets;
https://www.angloamerican.com/media/press-releases/2024/14-05-2024
"Anglo American has high confidence, backed by its proven track record in project delivery, to develop the Woodsmith project, which is currently on plan and on budget. In the near term, Anglo American will slow the development of the Woodsmith project to support Anglo American’s balance sheet deleveraging, with capex for critical studies and other activities expected to total $200 million in 2025 and no capex in 2026. Anglo American continues to recognise the asset’s unique resource and long term value potential and will complete critical technical studies in 2025 to then enable syndication for value with one or more strategic partners."
Https://www.turnerpope.com/wp-content/uploads/2024/05/Aptamer-Group-plc_28-3-2024_FINAL_BG.pdf
This is from March end (as for non-TP clients, it's released at least 1 month late) but still some useful comments, especially re CFlow:
"...Aptamer stated that in order to achieve a positive EBITDA and cash break even during the year ending 30 June 2025, it was targeting revenue of £3.0 million for current period rising to £6.0 million for the year ending 30 June 2026. While management prudently states that the first revenue target is likely to be missed, it nevertheless remains
possible to exceed this amount in the coming financial year, assuming the Group’s entire advanced pipeline will be
successfully converted along with delivery of all work-in-progress. Subject to change of course, the second revenue
target, along with ambition to achieve cash neutrality during FY2025/26, is now in place. .. this is not altogether unrealistic. Supporting such expectations, it is worth highlighting the extent of repeat business with large pharma partners, which presently includes work for a top 5 company to develop multiple Optimer® binders for different applications and no less than 18 separate contracts from two other top 15 partners. Elsewhere, the Group reports successful progression with Unilever for novel applications in FMCG, while entering a second phase of development with Neuro-Bio for Optimer® binders to enable Alzheimer’s disease lateral flow diagnostics. For the latter two, patent applications are currently being prepared."
..."transitioning of Neuro-Bio’s binders to a LFD development partner before the end of the calendar year";
"While the highly technical nature of such work means that lead times can often be relatively extended, continuing
to develop multiple new product opportunities within its rapidly emerging subsector of next generation affinity
ligands, for which APTA justifiably claims technological leadership, ensures a sticky and not particularly price
sensitive customer base. Breakthrough adoption of any of the Group’s patented novel applications by any of its
major partners could of course be transformative both financially (in terms of downstream licensing revenues) and
industrywide reputation."
Mozax, don't know, it tried to break through 0.90 twice, maybe 3rd time lucky?
Arron sounded bullish in the RNS, for me it was "certainty" of more contracts tb signed by June end; if it does indeed happen, then yes, SP should return to +1p.